FY2025 EPS Estimates for Haemonetics Decreased by Analyst

Haemonetics Co. (NYSE:HAE) – Research analysts at Zacks Research lowered their FY2025 EPS estimates for shares of Haemonetics in a report released on Thursday, March 13th. Zacks Research analyst R. Department now expects that the medical instruments supplier will post earnings of $4.54 per share for the year, down from their prior forecast of $4.56. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q4 2025 earnings at $1.21 EPS, Q1 2026 earnings at $1.11 EPS, Q2 2026 earnings at $1.22 EPS, Q3 2026 earnings at $1.34 EPS, Q4 2026 earnings at $1.34 EPS, FY2026 earnings at $5.00 EPS, Q1 2027 earnings at $1.37 EPS and FY2027 earnings at $5.73 EPS.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%.

A number of other equities research analysts have also recently commented on HAE. Raymond James reiterated a “strong-buy” rating and set a $115.00 target price (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. JPMorgan Chase & Co. began coverage on Haemonetics in a research note on Friday, December 6th. They set an “overweight” rating and a $116.00 target price on the stock. JMP Securities lowered their target price on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research note on Friday, February 7th. Needham & Company LLC lowered their target price on Haemonetics from $112.00 to $108.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Finally, Bank of America cut Haemonetics from a “neutral” rating to an “underperform” rating and lowered their target price for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $101.67.

Haemonetics Trading Down 1.0 %

NYSE HAE opened at $64.84 on Monday. The stock has a market capitalization of $3.26 billion, a price-to-earnings ratio of 25.53, a PEG ratio of 1.11 and a beta of 0.43. Haemonetics has a one year low of $58.80 and a one year high of $97.97. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The business’s fifty day moving average is $68.33 and its 200-day moving average is $75.34.

Institutional Investors Weigh In On Haemonetics

Hedge funds and other institutional investors have recently modified their holdings of the stock. TD Waterhouse Canada Inc. bought a new stake in shares of Haemonetics during the fourth quarter valued at about $25,000. Covestor Ltd increased its position in shares of Haemonetics by 146.8% during the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock valued at $58,000 after buying an additional 439 shares during the period. Whittier Trust Co. bought a new stake in shares of Haemonetics during the fourth quarter valued at about $62,000. Parkside Financial Bank & Trust increased its position in shares of Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after buying an additional 240 shares during the period. Finally, AlphaQuest LLC increased its position in shares of Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock valued at $143,000 after buying an additional 1,826 shares during the period. 99.67% of the stock is currently owned by institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.